Protein stabilizer portfolio
![Protein stabilizer portfolio](https://www.cphi-online.com/img/v2021/product_image.png)
Product Description
MERCK
![MERCK](https://www.cphi-online.com/MERCK_LOGO_Purple_RGB-comp286589.png)
-
FR
-
2020On CPHI since
-
4Certificates
-
5000+Employees
Company types
Primary activities
Categories
MERCK
![MERCK](https://www.cphi-online.com/MERCK_LOGO_Purple_RGB-comp286589.png)
-
FR
-
2020On CPHI since
-
4Certificates
-
5000+Employees
Company types
Primary activities
More Products from MERCK (9)
-
Product Deviron® C16 Detergent EMPROVE® EVOLVE
Deviron® C16 detergent provides robust inactivation of enveloped viruses. In addition, it may be used to achieve cell lysis for viral gene therapy vector production processes. It does not require a REACH authorization and is a suitable alternative to Triton™ X-100 detergent.
-
Product Meglumine
Meglumine is a versatile product applied either as a counterion to form a salt with the API or as a functional excipient. Traditionally applied as a counterion in contrast media, meglumine is an organic base which can also be used as a functional excipient to enhance API solubility, improve API stabili... -
Product Parteck® MXP (Polyvinyl alcohol 3-82) EMPROVE® ESSENTIAL Ph Eur
Poor solubility of APIs is a critical challenge in the drug development process. Our Parteck® MXP range of polymers includes two polyvinyl alcohol-based excipients, specifically designed and optimized for hot melt extrusion to increase solubility for a broad range of APIs.
With a lower de... -
Product Parteck® MXP (Polyvinyl alcohol 4-88) EMPROVE® ESSENTIAL Ph Eur,ChP,JPE,USP
Poor solubility of APIs is a critical challenge in the drug development process. Our Parteck® MXP range of polymers includes two polyvinyl alcohol-based excipients, specifically designed and optimized for hot melt extrusion to increase solubility for a broad range of APIs.
q... -
Product Parteck® PLX 188 (Poloxamer 188) (stabilized with 70ppm BHT) EMPROVE® ESSENTIAL Ph Eur,NF
Parteck® PLX 188 is a dissolution rate enhancing excipient that also acts as a robust water-soluble, hydrophilic lubricant. With its optimized particle size, Parteck® PLX 188 poloxamer is designed with the needs of modern manufacturing in mind - such as direct compression and continuous manufacturing -... -
Product Parteck® SLC 500 EMPROVE® ESSENTIAL Ph Eur,NF
Parteck® SLC mesoporous silica is a multi-functional excipient for both solubility enhancement and particle engineering.
When used as a solubility enhancing excipient, the high surface area and small pores of Parteck® SLC mesoporous silica enable optimal stabilization of the more solubl... -
Product Viscosity Reduction Platform
The Viscosity Reduction Platform of proprietary excipient combinations enables subcutaneous formulation of highly concentrated protein biologics, bringing together increased concentrations and improved downstream processing. -
Product API Processing portfolio
Choose API processing to improve API properties right from the start and avoid the risk of dealing with a poorly water-soluble API in formulation development or the need to start API development from scratch.
Whichever API processing method you decide to use, we pr... -
Product Benzonase® endonuclease portfolio
Benzonase® endonuclease is a unique, genetically engineered endonuclease that offers a variety of advantages over existing methods of nucleic acid removal. This enzyme has been designed to be supplied without protease activity and without the viral contaminants that can accompany enzymes isolated from ...
MERCK resources (8)
-
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
Brochure Accelerate dissolution
Enhance dissolution rate and lubrication with a single high performance excipient.
Parteck® PLX provides consistent performance, improved dissolution rate and reliable lubrication – all at the same time.
-
News Pharma CEOs write open letter calling suppliers to commit to sustainability
Several big pharma companies have added their names to a letter challenging suppliers in the healthcare industry to pledge to sustainability targets. -
Whitepaper Poloxamer: A simple and powerful solution for accelerating dissolution
Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of the molecule. For DCS Class IIa molecules, defined as having a slow dissolution rate, simple yet effective formulations can be developed. Parteck® PLX 188 excipient should be considered for these challenging molecules to increase dissolution rate, provide hydrophilic lubrication, and enable simple and costeffective manufacturing processes. -
News Merck tests new formulation of Keytruda before the patent runs out
Merck tests new formulation of effective immunotherapy Keytruda to gain approval in time to extend the patent on the drug before it runs out in 2028. -
Whitepaper Poloxamer: A simple and powerful solution for accelerating dissolution
Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of the molecule. For DCS Class IIa molecules, defined as having a slow dissolution rate, simple yet effective formulations can be developed. Parteck® PLX 188 excipient should be considered for these challenging molecules to increase dissolution rate, provide hydrophilic lubrication, and enable simple and costeffective manufacturing processes. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
Webinar Strategies and Enabling Technologies for Enhancing API Solubility
Development of new active pharmaceutical ingredients (APIs) is lengthy and cost-intensive, thus avoiding any potential risk that may limit the product’s success is of utmost importance. Today, many APIs are not being commercialized as they are poorly water soluble and, as a result, exhibit too low bioavailability.PLX, MXP, SLC, Meglumine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance